Literature DB >> 26642203

Correction: Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.

V Ramesh, Ruchi Singh, Kumar Avishek, Aditya Verma, Deepak Kumar Deep, Sandeep Verma, Poonam Salotra.   

Abstract

Entities:  

Year:  2015        PMID: 26642203      PMCID: PMC4671613          DOI: 10.1371/journal.pntd.0004289

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


× No keyword cloud information.
Fig 3 and Fig 4 are incorrect. The authors have provided corrected versions here.
Fig 3

Scatter plot showing parasite load at the pre-treatment stage in the cases that eventually relapsed vs those that remained cured.

Parasite load was determined by Q-PCR in slit aspirate sample at the time of diagnosis of PKDL and expressed as the number of Leishmania parasite/μl slit aspirate. P value was calculated using Mann-Whitney test. Horizontal bars indicate mean± SEM.

Fig 4

In vitro MIL susceptibility of parasite isolates from cured (n = 7) and relapsed (n = 6) PKDL patients.

MIL susceptibility at (A) promastigote stage (B) amastigote stage. Each individual value represents mean IC50± SD of the results from two separate assays. P value was calculated using Mann-Whitney test. Horizontal bars indicate mean ±SEM

Scatter plot showing parasite load at the pre-treatment stage in the cases that eventually relapsed vs those that remained cured.

Parasite load was determined by Q-PCR in slit aspirate sample at the time of diagnosis of PKDL and expressed as the number of Leishmania parasite/μl slit aspirate. P value was calculated using Mann-Whitney test. Horizontal bars indicate mean± SEM.

In vitro MIL susceptibility of parasite isolates from cured (n = 7) and relapsed (n = 6) PKDL patients.

MIL susceptibility at (A) promastigote stage (B) amastigote stage. Each individual value represents mean IC50± SD of the results from two separate assays. P value was calculated using Mann-Whitney test. Horizontal bars indicate mean ±SEM
  1 in total

1.  Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.

Authors:  V Ramesh; Ruchi Singh; Kumar Avishek; Aditya Verma; Deepak Kumar Deep; Sandeep Verma; Poonam Salotra
Journal:  PLoS Negl Trop Dis       Date:  2015-10-22
  1 in total
  3 in total

1.  Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani.

Authors:  Aditya Verma; Vasundhra Bhandari; Deepak Kumar Deep; Shyam Sundar; Jean Claude Dujardin; Ruchi Singh; Poonam Salotra
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2017-10-10       Impact factor: 4.077

2.  Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.

Authors:  Deepak Kumar Deep; Ruchi Singh; Vasundhra Bhandari; Aditya Verma; Vanila Sharma; Saima Wajid; Shyam Sundar; V Ramesh; Jean Claude Dujardin; Poonam Salotra
Journal:  PLoS Negl Trop Dis       Date:  2017-06-02

3.  Non-human primates and Leishmania immunity.

Authors:  Sonia André; Vasco Rodrigues; Morgane Picard; Ricardo Silvestre; Jérôme Estaquier
Journal:  Cytokine X       Date:  2020-10-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.